In fact there were two good news items, one about a big move into immuno therapy to treat cancer!!!
In fact there has been a string of great news.
NVS News: New indication for Novartis bone marrow disorder drug cleared in Europe 03/17/2015 07:35:19 AM NVS News: Wall Street Breakfast: Japan Marches Higher As Nikkei Breaches 19,000 03/13/2015 06:30:41 AM NVS News: Cellectis: Finding Value In A Crowded CAR-T Space 03/10/2015 09:51:04 PM NVS News: Ophthotech earns $50M Fovista milestone from Novartis 03/10/2015 07:48:59 AM NVS News: Arrowhead buys Novartis' RNAi assets 03/05/2015 08:06:10
The European Commission approves Novartis' (NYSE:NVS) Jakavi (ruxolitinib) for the treatment of adult patients with polycythemia vera (PV) who are resistant to or intolerant of hydroxyurea. Polycythemia vera is a rare blood cancer associated with the overproduction of blood cells, principally red blood cells. It is caused by a mutation in the Janus kinase 2 (JAK2) gene. It affects ~180K people in the European Union.
The goal of treatment is to reduce the thickness of the blood and prevent bleeding and clotting. If left untreated, the disorder can lead to blood clots, stroke and heart attack. About 25% of PV patients develop resistance to or intolerance of hydroxyurea and are considered to have uncontrolled disease.
Jakavi is an oral inhibitor of the JAK1 and JAK2 tyrosine kinases. It was previously approved for the treatment of myelofibrosis, a disorder of the bone marrow in which the marrow is replaced by scar tissue.
Novartis licensed ruxolitinib from Incyte (NASDAQ:INCY) for development and commercialization ex-U.S. Incyte retains commercialization rights in the U.S.
Market Data 
Markets 
AI
